Havana: Several research projects and clinical trials are currently underway with drugs developed in Cuba to address the current epidemiological situation with dengue and chikungunya viruses, both of which are transmitted throughout almost the entire country. This was confirmed by Francisco Dur¡n, National Director of Epidemiology at the Cuban Ministry of Public Health, in the most recent edition of the radio and television program Mesa Redonda.

According to Lao News Agency, Dur¡n emphasized that 21 research projects are actively being conducted to tackle this health issue, drawing parallels to the country’s approach towards COVID-19. Among these initiatives are two clinical trials focusing on patients in the chronic and subacute phases following chikungunya infection. These trials are evaluating the safety and therapeutic effect of Jusviza, an injectable drug aimed at controlling hyperinflammation, regulating the immune response, and reducing mortality risk in severe or critical COVID-19 patients.

Furthermore, a trial is in progress to assess the effects, safety, and tolerability of rectal ozone therapy for patients experiencing joint symptoms after the acute phase of chikungunya. Another study is examining the protective effect of Cumeric, nasal drops with turmeric as the active ingredient, on the clinical progression of this arboviral disease.

The health intervention plan includes the use of Biomodulin T and Thymalin in at-risk populations in Havana, particularly targeting adults aged 70 to 74, as well as residents of the social protection center in the Cotorro district. Additionally, research is being conducted on the teratogenic effects of congenital chikungunya infection in pregnant women and newborns.

Dur¡n described the current epidemiological scenario as complex due to the presence of arboviruses like dengue and chikungunya, though he noted a downward trend in their circulation.